18+ ONLY · LAB RESEARCH ONLY · NOT FOR HUMANS OR ANIMALS

← BSR Intelligence

Research Pipeline · 15 Nov 2026

ObesityWeek 2026: EloraTZP Phase 2 Data and Orforglipron's China Approval Signal Lilly's Next Phase in the GLP-1 Pipeline

Eli Lilly is presenting a broad cardiometabolic portfolio at ObesityWeek 2026 this weekend, headlined by Phase 2 results for EloraTZP — an investigational combination of the amylin receptor agonist eloralintide and tirzepatide — alongside new retatrutide sleep apnea data. Separately, China's NMPA approved orforglipron on 12 November, making it the first oral GLP-1 treatment for weight management in the world's second-largest pharmaceutical market.

12 sources cited

Key takeaways

  • Eli Lilly is presenting new clinical data across four assets at ObesityWeek 2026 (14–17 November, Washington DC), including Phase 2 results for EloraTZP — an investigational combination of eloralintide and tirzepatide — showing 23.3% mean body-weight reduction at 48 weeks in adults with obesity and type 2 diabetes.
  • Phase 3 retatrutide data from TRIUMPH-1, TRIUMPH-2, and TRIUMPH-4 are being formally presented at the same conference, with the triple agonist reducing obstructive sleep apnea (OSA) severity by up to 60.6% over 80 weeks.
  • On 12 November 2026, China's National Medical Products Administration (NMPA) approved orforglipron (Foundayo) for weight management, making it the first oral GLP-1 receptor agonist to receive that designation in China.
  • Taken together, the three developments illustrate Lilly's strategy of expanding the GLP-1 and amylin combination space while simultaneously broadening its geographic footprint for approved assets.

EloraTZP Phase 2: an amylin-GLP-1 combination in obesity and type 2 diabetes

Eli Lilly's press release confirms that ObesityWeek 2026 features an oral session today (Sunday, 15 November) presenting Phase 2 results for EloraTZP, described as an investigational combination of eloralintide and tirzepatide. The session is scheduled for 3:30–4:30 p.m. Eastern Time.

Medscape's earlier reporting on the data, presented initially at EASD 2026, provides mechanistic context: eloralintide is a once-weekly selective amylin receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist — the two compounds therefore engage three distinct hormonal pathways involved in appetite and glycaemic regulation.

The Phase 2 trial (NCT06603571) evaluated eloralintide alone and in combination with tirzepatide across ten dose arms over 48 weeks in adults with obesity or overweight and type 2 diabetes. According to Lilly's investor release:

  • EloraTZP delivered weight loss of up to an average of 54.1 lbs (23.3%) at 48 weeks from an average baseline of 232.4 lbs, with up to 60% of participants no longer meeting the BMI criteria for obesity.
  • The combination lowered HbA1c by up to an average of 2.9 percentage points, with up to 77% of participants achieving normal blood sugar levels.

The Lilly clinical data page shows that at week 48, the eloralintide plus tirzepatide combination produced body-weight reductions up to −23.3%; all eloralintide-alone and combination arms differed from placebo at p<0.001. By comparison, Medscape's reporting notes that tirzepatide monotherapy at 15 mg produced mean weight loss of 14.8% — a meaningful separation from the highest combination dose.

The adverse-event profile observed in the Phase 2 study is worth noting for researchers contextualising the biology: Lilly's clinical data indicate that fatigue and vomiting with eloralintide alone were similar to placebo rates, though nausea, fatigue, and vomiting were higher with the highest combination arm (eloralintide 3/6/9 mg plus tirzepatide 15 mg) than with tirzepatide alone.

Participant-reported outcomes add a secondary dimension. Lilly's ObesityWeek release notes that in Phase 2 exit interviews at 48 weeks, 74% of eloralintide-treated participants reported fewer food cravings — particularly for sugary foods — and 52% reported less food noise. Among those who consumed alcohol at baseline, 41% reported reduced intake.

Medscape further reports that Lilly plans to initiate Phase 3 studies of a co-formulated eloralintide and tirzepatide product by the end of 2026, using an optimised dose-escalation schedule. Eloralintide is additionally being evaluated as monotherapy in ongoing Phase 3 obesity trials. A co-formulated Phase 3 programme (NCT07881458) for EloraTZP in adults with obesity or overweight and type 2 diabetes has been posted to ClinicalTrials.gov, with Eli Lilly as sponsor.

For UK research procurement teams, eloralintide's mechanism as an amylin receptor agonist is scientifically distinct from GLP-1 and GIP pathways already well represented in research catalogues. The compound's peptide backbone — it is delivered as a subcutaneous injection — places it squarely within the domain of interest to peptide research suppliers, particularly as Phase 3 scale-up will require robust SPPS manufacturing capacity.


Retatrutide at ObesityWeek: sleep apnea and osteoarthritis readouts

Also presented at ObesityWeek 2026 today are Phase 3 data from the TRIUMPH programme for retatrutide, Lilly's investigational GIP, GLP-1, and glucagon triple receptor agonist. While a previous BSR Intelligence briefing covered the TRIUMPH-4 and TRIUMPH-1-OA weight-loss and osteoarthritis data, the sleep apnea results are receiving their formal ObesityWeek oral presentation on 15 November.

Lilly's conference release states that in TRIUMPH-1, retatrutide reduced the apnea-hypopnea index (AHI) by an average of 36.1 events per hour (60.6%) at 80 weeks in adults with moderate-to-severe OSA and obesity or overweight. In TRIUMPH-2, which enrolled patients who also had type 2 diabetes, the reduction was 28.4 events per hour (48.1%) at 80 weeks.

MedicalXpress reported that among participants receiving higher retatrutide doses, 39%–52% saw their sleep apnea improve to either no disease or mild disease without excessive daytime sleepiness, compared with approximately 13% in the placebo group. Additionally, Lilly's release notes that in TRIUMPH-4, retatrutide reduced knee osteoarthritis pain by an average of 4.5 points (75.8%) on the WOMAC pain subscale at 68 weeks.

The safety profile for retatrutide in these trials was described as generally consistent with previous studies, with the most common adverse events being gastrointestinal in nature.


Orforglipron approved in China: first oral GLP-1 for weight management

On 12 November 2026, China's National Medical Products Administration (NMPA) approved orforglipron for weight management in adults with obesity, or overweight with at least one weight-related comorbidity, alongside diet control and increased physical activity. Allsci reports that the drug will be marketed in China under the brand name Muyouda, distinct from its US name Foundayo.

Pharmaphorum notes that this makes orforglipron the first oral GLP-1 agonist to receive marketing authorisation for weight management in China, where patients have previously had access only to injectable treatments including Lilly's tirzepatide and Novo Nordisk's semaglutide. Novo Nordisk's application for oral Wegovy (semaglutide) in China remains under NMPA review, giving Lilly a regulatory head start in what J.P. Morgan estimates could become a RMB 30 billion ($4.5 billion) annual market for GLP-1 weight-management treatments over the next five to seven years.

Orforglipron is notably a small-molecule, non-peptide GLP-1 receptor agonist — as confirmed by Pharmaphorum — which differentiates it structurally from the peptide-based GLP-1 agents (semaglutide, tirzepatide, liraglutide). A separate marketing application for orforglipron in type 2 diabetes is currently under NMPA review, an indication in which Novo Nordisk already holds Chinese approval for oral semaglutide.

Yahoo Finance reports that Foundayo recorded $184 million in US revenue in Q3 2026, bringing total revenue since its April 2026 US launch to $281 million. The compound was approved by the MHRA in August 2026 for use in the UK, and the EMA recommended approval for adults with obesity last month, according to Yahoo Finance — meaning the compound now has three major regulatory grants within a seven-month window.

For UK research organisations, the orforglipron China approval has limited direct procurement implications, since it involves a small-molecule compound rather than a peptide reference standard. However, its global regulatory momentum is relevant as a comparator benchmark for researchers designing GLP-1 receptor agonist studies and assessing which molecules are likely to form part of approved combination regimens alongside future peptide assets.


Procurement and research context

The ObesityWeek 2026 presentations collectively illustrate several trends of relevance to UK peptide research procurement:

Amylin combination biology: The EloraTZP Phase 2 results give weight to amylin receptor agonism as a productive adjunct to GLP-1–based pharmacology. Procurement teams sourcing reference standards for mechanistic research should note that eloralintide's selectivity for amylin receptors — in contrast to pramlintide, which is a non-selective amylin analogue — may prompt demand for characterised amylin receptor agonist peptides in research settings.

Broad indication expansion: The TRIUMPH data on sleep apnea and osteoarthritis reinforce that incretin-based peptides are being evaluated well beyond weight and glycaemia — a pattern also visible in tirzepatide's adolescent data (SURMOUNT-ADOLESCENTS showing 21.4% mean BMI reduction at 72 weeks), also presented at ObesityWeek. Researchers studying comorbidity mechanisms may need to track these expanded trial endpoints when planning comparative peptide studies.

Supply-chain signals: As Lilly advances multiple late-stage peptide programmes simultaneously (eloralintide monotherapy Phase 3, co-formulated EloraTZP Phase 3, retatrutide regulatory preparation), demand for validated peptide manufacturing intermediates and reference standards is likely to continue rising. This comes alongside the ongoing Samsung Biologics / PolyPeptide CDMO consolidation and Shilpa CDMO's capacity investment, suggesting the supply-side is responding to anticipated clinical-stage volume.

COMPOUNDS IN THIS BRIEFING

Research-grade material, HPLC verified, certificate of analysis with every order.

THE WEEKLY BRIEFING

The week's Intelligence in one email, every Friday morning.

Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.

Published by BSR — Biotech Scientific Research. For research and laboratory use only · not for human consumption.

More in Research Pipeline